Share

Leading magazines publish interview with BSP signatory Georges Rawadi and co-author John Maraganore

On 29 March 2022, leading business weekly magazine Usine Nouvelle published an interview with signatory of the Biotech Social Pact (BSP), Georges Rawadi, former CEO of Ysopia Biosciences and member of the board at Apmonia Therapeutics and Alia Therapeutics, and co-author of the BSP John Maraganore, former CEO and founder of Alnylam Pharmaceuticals. The interview has also been published in the monthly pharma magazine Industrie Pharma.

Georges Rawadi and John Maraganore call for more investments in the European biotech sector and a better reimbursement model. “The Social Contract for Biotechnology will be to create a platform bringing together the different actors to propose sustainable and alternative business models,” Rawadi said.

You can access the full interview on Usine Nouvelle.







						

				

					

		

					

		

				

				

				

					

		

					

		

							

				

				

					

								

						

					

			

						

				

			
The Biotech Social Pact gathers CEOs and leaders of biotech and life sciences who are committed to working alongside high-level policymakers and health authorities to sustainably grow the biotech ecosystem whilst ensuring timely and widespread access to innovative treatments for patients and health systems across Europe. The Biotech Social Pact does not necessarily reflect the policies or positions of the agencies, organizations, employers, or companies with which the signatories are affiliated. United in upholding common principles and beliefs, our members are diverse assembly of leading organisations that are often not represented in trade associations, including pre- and early commercial companies, venture capital firms and individual industry leaders. The BSP is not a trade association and coexists alongside existing biopharma trade associations. It aims at offering a supporting voice to emerging and rapidly growing global biotech companies and to contribute to awareness of biotech and support the biotech ecosystem at large. Up until 2023, the Biotech Social Pact was managed by Portland, a global Public Affairs company, with the financial support of Alnylam Pharmaceuticals, Amicus and argenx.